MA53873A - Compositions et procédés pour le traitement de la presbytie - Google Patents

Compositions et procédés pour le traitement de la presbytie

Info

Publication number
MA53873A
MA53873A MA053873A MA53873A MA53873A MA 53873 A MA53873 A MA 53873A MA 053873 A MA053873 A MA 053873A MA 53873 A MA53873 A MA 53873A MA 53873 A MA53873 A MA 53873A
Authority
MA
Morocco
Prior art keywords
presbyopia
compositions
treatment
methods
Prior art date
Application number
MA053873A
Other languages
English (en)
Inventor
Gerald Horn
Original Assignee
Presbyopia Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc
Publication of MA53873A publication Critical patent/MA53873A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/1412Containers with closing means, e.g. caps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA053873A 2018-10-10 2019-10-08 Compositions et procédés pour le traitement de la presbytie MA53873A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862743720P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
MA53873A true MA53873A (fr) 2022-01-19

Family

ID=70161531

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053873A MA53873A (fr) 2018-10-10 2019-10-08 Compositions et procédés pour le traitement de la presbytie

Country Status (12)

Country Link
US (1) US10836760B2 (fr)
EP (1) EP3863630A4 (fr)
JP (1) JP2022504746A (fr)
KR (1) KR20210076941A (fr)
CN (1) CN113518620A (fr)
AU (1) AU2019357979A1 (fr)
BR (1) BR112021006618B1 (fr)
CA (1) CA3114204A1 (fr)
MA (1) MA53873A (fr)
MX (1) MX2021004183A (fr)
SG (1) SG11202103033WA (fr)
WO (1) WO2020076769A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222525A1 (fr) * 2020-04-30 2021-11-04 Eye Therapies, Llc Compositions de brimonidine et procédés d'utilisation
EP4228636A1 (fr) * 2020-10-13 2023-08-23 Lenz Therapeutics, Inc. Compositions et procédés pour des médicaments ophtalmiques stables au stockage
WO2022232205A1 (fr) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. Procédé de réduction de douleur de sourcil
CN116459251A (zh) * 2022-01-18 2023-07-21 苏州普乐康医药科技有限公司 一种含西维美林的眼用制剂及其制备方法和应用
TW202329958A (zh) * 2022-01-25 2023-08-01 張金明 西維美林水溶液組合物和使用方法
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508751A (ja) * 1992-07-02 1995-09-28 テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド 老視治療のための方法および生産品
US20090297566A1 (en) * 2004-12-27 2009-12-03 Brinkman Kyle R Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
US10307408B2 (en) * 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US9320709B2 (en) * 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US20190038609A1 (en) * 2013-08-28 2019-02-07 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
BR112021006618B1 (pt) 2022-09-27
BR112021006618A2 (pt) 2021-07-06
AU2019357979A1 (en) 2021-04-29
SG11202103033WA (en) 2021-04-29
JP2022504746A (ja) 2022-01-13
MX2021004183A (es) 2021-10-26
WO2020076769A1 (fr) 2020-04-16
US10836760B2 (en) 2020-11-17
US20200115377A1 (en) 2020-04-16
CN113518620A (zh) 2021-10-19
EP3863630A1 (fr) 2021-08-18
EP3863630A4 (fr) 2022-06-29
CA3114204A1 (fr) 2020-04-16
KR20210076941A (ko) 2021-06-24

Similar Documents

Publication Publication Date Title
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
MA47719A (fr) Esketamine pour le traitement de la dépression
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA48637A (fr) Polythérapies pour le traitement du cancer
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA50409A (fr) Polythérapies pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
MA55087A (fr) Compositions et procédés de traitement de laminopathies
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation